Denceptor Therapeutics

Denceptor Therapeutics Ltd. is developing a technology to induce antigen-specific T-cell responses, which the company believes is more effective than other dendritic cell-targeting approaches for cancer. The company is dedicated to innovative liver-directed gene therapy for treating bleeding disorders and other debilitating chronic diseases.